Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

Dabrafenib plus trametinib combination is approved in Europe for V600E-mutant metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to assess efficacy and safety of this combination in a real-world setting. This retrospective multicentric study included 40 patients with adva...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-12, Vol.12 (12), p.3608
Main Authors: Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Format: Article
Language:English
Subjects:
Age
Brief Report
Cancer
Chemotherapy
Clinical trials
FDA approval
Immunotherapy
Kinases
Life Sciences
Melanoma
Metastases
Metastasis
Mutants
Mutation
Non-small cell lung carcinoma
Patients
Small cell lung carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dabrafenib plus trametinib combination is approved in Europe for V600E-mutant metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to assess efficacy and safety of this combination in a real-world setting. This retrospective multicentric study included 40 patients with advanced NSCLC harboring V600E mutation and receiving dabrafenib plus trametinib. The median progression-free survival (PFS) and overall survival (OS) were 17.5 (95% CI 7.1-23.0) months and 25.5 (95% CI 16.6-not reached) months in the entire cohort, respectively. For the 9 patients with first-line treatment, median PFS was 16.8 (95% CI 6.1-23.2) months and median OS was 21.8 (95% CI 1.0-not reached) months; for the 31 patients with second-line or more treatments, median PFS and OS were 16.8 (95% CI 6.1-23.2) months and 25.5 (95% CI 16.6-not reached) months, respectively. Adverse events led to permanent discontinuation in 7 (18%) patients, treatment interruption in 8 (20%) and dose reduction in 12 (30%). In conclusion, these results suggest that efficacy and safety of dabrafenib plus trametinib combination in patients with V600E metastatic NSCLC are comparable in a real-world setting and in clinical trials for both previously untreated and treated patients.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12123608